CLOSED
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the. Track Ajanta Pharma Limited's live NSE:AJANTPHARM share price ₹3,516.40 (+1.34%), market cap ₹₹439B, P/E 38.7. MarketRipple's AI analysis covers the investment thesis, ripple-chain impact, and Healthcare sector outlook for AJANTPHARM — real-time NSE India stock intelligence.
Ajanta Pharma Limited
03 August 2026 ·NSE
Market Cap
₹439B
PE Ratio
38.7
Dividend
1.85%
AI Score
57/100
Open
₹3,485.50
High
₹3,540.00
Low
₹3,476.20
Prev. Close
₹3,470.00
52W High
₹3,598.80
52W Low
₹2,329.90
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the
Key Takeaway
Ajanta Pharma Limited is rated buy with a P/E of 38.7x — understand the valuation context before sizing a position.
★ Recommended
Ask AI: Is Ajanta Pharma Limited fairly valued right now?
Because a P/E of 38.7x needs to be compared against sector peers and growth expectations to be meaningful.
Continue Research
View events affecting Ajanta Pharma Limited
Because the investment case must account for macro and company-specific developments — events reveal the 'why' behind price moves.
Trace sector ripple effects
Because Healthcare moves create upstream and downstream implications that affect the entire thesis.
Intelligence Path
Growth
Govt Exposure
Policy Dependence
Execution Quality
News Sensitivity
Debt Strength
1,626 Cr
Revenue
334 Cr
Net Profit
0%
ROE
0%
ROCE
90.79
EPS
| ₹ in Crore | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 3,708 | 4,162 | 4,588 | 5,407 | 5,726 |
| Net Profit | 588 | 816 | 920 | 1,056 | 1,130 |
| ROE (%) | — | — | — | 0.0% | 0.0% |
| EPS (₹) | — | — | — | 90.79 | 90.79 |
| Debt/Equity | — | — | — | 5.7 | 5.7 |